{"name":"Celldex Therapeutics","slug":"celldex","ticker":"CLDX","exchange":"NASDAQ","domain":"celldex.com","description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.","hq":"Hampton, NJ, USA","founded":0,"employees":"198","ceo":"Anthony S. Marucci","sector":"Autoimmune / Oncology","stockPrice":32.62,"stockChange":0.11,"stockChangePercent":0.34,"marketCap":"$2.6B","metrics":{"revenue":1764000,"revenueGrowth":-97.8,"grossMargin":0,"rdSpend":245074000,"netIncome":-258757000,"cash":451457984,"dividendYield":0,"peRatio":-7.2,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"varlilumab patent cliff ($0.0B at risk)","drug":"varlilumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CDX1307","genericName":"CDX1307","slug":"cdx1307","indication":"Other","status":"phase_1"},{"name":"CDX-011","genericName":"CDX-011","slug":"cdx-011","indication":"Other","status":"phase_2"},{"name":"CDX-585","genericName":"CDX-585","slug":"cdx-585","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CDX1307","genericName":"CDX1307","slug":"cdx1307","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CDX-011","genericName":"CDX-011","slug":"cdx-011","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CDX-585","genericName":"CDX-585","slug":"cdx-585","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Celldex Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Varlilumab in Combination with Nivolumab","summary":"Celldex Therapeutics announced that the FDA has cleared the IND application for varlilumab in combination with nivolumab for the treatment of patients with unresectable or metastatic melanoma.","drugName":"varlilumab","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Celldex Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Celldex Therapeutics reported its third quarter 2023 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Celldex Therapeutics Enters into License Agreement with Incyte Corporation","summary":"Celldex Therapeutics entered into a license agreement with Incyte Corporation for the development and commercialization of varlilumab in combination with Incyte's epacadostat.","drugName":"varlilumab","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"trial","source":"simplywall.st","summary":"A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data - simplywall.st","headline":"A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOT1kxcDg1ZF9zd3ZOMVBTRHM3Yi1QbnozZGNBcG5NbDFRNzJIcWM3ZzRXQWJJRVBFLVcxRXBHU2ZSZTIzUC0wdjdNVXpjTXZHbjIwQ0I0blNhSHJvemlDNnNybC13cTNFQ3IyN20wZmZoSE8tLVVmZ2k1bFdEVVFwY24zMDJGclh3M3o4d0t6a3VEck5IdWpXR0RvWTlnbm15YmZaWDNyUFBwaXRkU2VrZTk5Nmp0YWdtdmJvODU0c3I1WFpENExzWDd4SXkzUDdjWXVIZFdDRGtFZVN3VUlnM1owTjBVenpNN1HSAe8BQVVfeXFMT2Rya1RhOFJhcl9GQjhLY0JvWXZBRFJ0bTJDOUJuczItUDc2MklpRTBwTXRZWEVMbGlhc2hXbVVRZjRkZlRoeWpCbmFNa0MwOC1aRFdCU3NPSDJxLVQ5VEZTQkFsZmE2WmxYYnRBUjFScDViT3lYT2xlRkp2MFN5WEpRZl9IZi01b0xNOWVuQzVydU9yMlp3Z0NGTG1ncWNaNWY2dDVpOWVvN08ta1dMdnNqQ2ROZFRwQVZQLVhOc0luS0RudHlWbXRWWDAyMjNaYjBDNkFXdGdKMDlpWGw5Nm9lVzFRanF5aS13NWJaeU0?oc=5","date":"2026-03-30","type":"pipeline","source":"simplywall.st","summary":"A Look At Celldex Therapeutics (CLDX) Valuation As Shares Show Renewed Momentum - simplywall.st","headline":"A Look At Celldex Therapeutics (CLDX) Valuation As Shares Show Renewed Momentum","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"trial","source":"simplywall.st","summary":"Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - simplywall.st","headline":"Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZmc5bkF1ZHFzZHRieWJCTFducUZRTHhKcUg2Ml9iUDAzek9aaURtbHVCVTF4d0Q2SDRHU3pkUUNjQmNBc1VnTjhnRHpzRG1nby1iWlp1Nm00T3NzS1RUMXhvdVprWE1xMWczSlA3d0xKcENlMV9nZDEyZmVKQ00xczR4TlpfaVVOeFh4djF6cXE3M01p?oc=5","date":"2026-02-27","type":"pipeline","source":"Yahoo Finance","summary":"Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential - Yahoo Finance","headline":"Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcWNfZnlaSWxaWjlURG1sdS1SaFUxZ0NrLVhMNEtPenJYM3ZTaFE2WGc4SGFETm1UNm9xOEFOWXNEMmlwQ2FWRlc0ZnMtUUNGZG82ZEJIU0pPTmZiXzBYLWtIOURyYjNHSWtsT2Z3U093bVdYS2dtdXlRWEVCMm10VUZWQUJYVTNvQWZhdEFKcjF1TU53NTROc3pVRTlZTDE3a0M4UmtoaHVyc2x6aG44dFZ5WXM1Y2FjZUhSNkZR?oc=5","date":"2026-02-26","type":"regulatory","source":"TechStock²","summary":"Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone - TechStock²","headline":"Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOdHpNZDJ4X3lQRHFVSXhRVGxCNHZNWUp6ZnJmLVpoZHBaUGlMSTJFYnlEYkk3Y3lKbllCcWhLeElrZkJtTzNra21VVEJVTHlGaU1Qb19xNzJOclhRYWVvTHZLTzdBemozTkRsUEM5d3I1TkJ4R2FreVBfSVZzVkgyay1RdVotZmw4RDhHOWRyRklMME41Yk9pVU91UWZXcUVBeDNYM242WkFxa0JNclZiRkM2UDM0eElBZFhyY0lFaDdhUmhu?oc=5","date":"2026-02-25","type":"pipeline","source":"Stocktwits","summary":"CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent - Stocktwits","headline":"CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQRGoyS0laZjkyOXhQM1F5LTRSRXZYWTdXNzJ6Y1pkMGtQREFBY0JYNmFiT1hYbzBERnhWVldaeGJtMUFOMWU2aUZHUkhPLWI2YXRUN1lXSDFFdUhMZ2FVV2JfQ04xU3ZJMjBZWVRhdXJDcGxGQTN3Vi0yQjRnTFlaQ2V3TGMzdjNlYkhfeE5ISjladXlsZFhoU1dxVXBQaV9vNkJtSDlnX1JwT2xTSWZNZkxHbklUOFducU1oYjF2ZlBJaERTRXVR?oc=5","date":"2026-01-05","type":"deal","source":"AD HOC NEWS","summary":"Celldex Therapeutics Is Suddenly Everywhere: Smart Buy or Viral Mirage? - AD HOC NEWS","headline":"Celldex Therapeutics Is Suddenly Everywhere: Smart Buy or Viral Mirage?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBXUUdvLTBYbGwwcVBfTi1TYmdybmIyMHlnWTZSRUo2RWd3OG1BRUIzc3dER0lOUHZ3QkdyV051OXJrREhfWVk2SEFBdVpOaG1Kc243Nm9yR2JwY2hEWkZJajljMFJSZTNB?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"Celldex Therapeutics (CLDX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Celldex Therapeutics (CLDX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5qR2stVVdZQWNxSnVXdE1uRHd6NlRfU05hRWpjcWE4OVRwY042NXZjaWUzSHFJMWhYYy1YM01PVGI3eFZWNjNQQVg2TG9xWmVQ?oc=5","date":"2023-11-08","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQdS1vTGJLOTRpTzdYdXlETnZqRHhKcjNfY0RuMTBEUGRWLTVzanh0cEpXWVlNcFdGcU11aFhhQmJKXy1fWFB3Y2p0bmNjczRISHZYblp3MnIzN3ZRRERCZS00N0hyVzN5U1pfNXhkeW0wQjRSQzV1a2JTT3VKRWJQdg?oc=5","date":"2020-04-28","type":"pipeline","source":"MarketBeat","summary":"Top Celldex Therapeutics (CLDX) Competitors 2026 - MarketBeat","headline":"Top Celldex Therapeutics (CLDX) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE45ZThzS3djTDZrRWlsYUVuNUtZVFQ2UWxmYlFZdWNCZzBzdkJPTDFYcDdFTHBHTVFMdGhCd0E2M3p0bWlXVmJoSXJLSlg1cTVOamc?oc=5","date":"2017-05-10","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Celldex Therapeutics, Inc. (CLDX) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Celldex Therapeutics, Inc. (CLDX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNeXZfQVZvaWJ1aHk3NlhDNDNFVi12OTNhdWhpSGxZVFMyQXlIX095YWhBMElCZmhEZ1VxYTFMc0xRaUdNZmpxdWo5bUh0Vm1heGtUMEJYMF9TeVU3dGFJMkpnc2xDZHNvMmpLbnlwZF9rTTBxMWJoSGV5SzZ6dWtZcWIxRmxUWXRDOUNmTw?oc=5","date":"2013-07-03","type":"pipeline","source":"Insider Monkey","summary":"Celldex Therapeutics, Inc. (CLDX) On The Rise - Insider Monkey","headline":"Celldex Therapeutics, Inc. (CLDX) On The Rise","sentiment":"neutral"}],"patents":[{"drugName":"varlilumab","drugSlug":"varlilumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Autoimmune Diseases","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":1764000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":1764000,"period":"2018-12-31"},{"value":941000,"period":"2018-09-30"},{"value":2763000,"period":"2018-06-30"},{"value":4068000,"period":"2018-03-31"},{"value":12743000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":245074000,"rdSpendHistory":[{"period":"2025-12-31","value":245074000},{"period":"2024-12-31","value":163550000},{"period":"2023-12-31","value":118011000},{"period":"2022-12-31","value":82258000}],"sgaSpend":43838000,"operatingIncome":-287367000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-287367000},{"period":"2024-12-31","value":-195078000},{"period":"2023-12-31","value":-142042000},{"period":"2022-12-31","value":-107096000}],"netIncome":-258757000,"netIncomeHistory":[{"period":"2025-12-31","value":-258757000},{"period":"2024-12-31","value":-157863000},{"period":"2023-12-31","value":-141429000},{"period":"2022-12-31","value":-112325000}],"eps":-2.45,"epsHistory":[{"period":"2024-12-31","value":-2.45},{"period":"2023-12-31","value":-2.92},{"period":"2022-12-31","value":-2.4},{"period":"2021-12-31","value":-1.64}],"cash":28871000,"cashHistory":[{"period":"2025-12-31","value":28871000},{"period":"2024-12-31","value":28356000},{"period":"2023-12-31","value":34814000},{"period":"2022-12-31","value":29429000}],"totalAssets":582983000,"totalLiabilities":55818000,"totalDebt":2336000,"equity":527165000,"operatingCashflow":-210945000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-210945000},{"period":"2024-12-31","value":-157778000},{"period":"2023-12-31","value":-107291000},{"period":"2022-12-31","value":-103732000}],"capex":-2714000,"capexHistory":[{"period":"2025-12-31","value":-2714000},{"period":"2024-12-31","value":-1919000},{"period":"2023-12-31","value":-1818000},{"period":"2022-12-31","value":-1828000}],"freeCashflow":-213659000,"dividendsPaid":null,"buybacks":null,"employees":198,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11941000,"ebit":-87153000,"ebitda":-86337000,"period":"2025-12-31","revenue":121000,"epsBasic":-1.22,"netIncome":-81317000,"rdExpense":75333000,"epsDiluted":-1.22,"grossProfit":null,"operatingIncome":-87153000},{"sga":10686000,"ebit":-73617000,"ebitda":-72793000,"period":"2025-09-30","revenue":0,"epsBasic":-1.01,"netIncome":-67044000,"rdExpense":62931000,"epsDiluted":-1.01,"grossProfit":null,"operatingIncome":-73617000},{"sga":10391000,"ebit":-63857000,"ebitda":-62984000,"period":"2025-06-30","revenue":730000,"epsBasic":-0.85,"netIncome":-56600000,"rdExpense":54196000,"epsDiluted":-0.85,"grossProfit":null,"operatingIncome":-63857000},{"sga":10820000,"ebit":-62739000,"ebitda":-61872000,"period":"2025-03-31","revenue":695000,"epsBasic":-0.81,"netIncome":-53796000,"rdExpense":52614000,"epsDiluted":-0.81,"grossProfit":null,"operatingIncome":-62739000},{"sga":10263000,"ebit":-56027000,"ebitda":-55208000,"period":"2024-12-31","revenue":1175000,"epsBasic":-0.71,"netIncome":-47092000,"rdExpense":46939000,"epsDiluted":-0.71,"grossProfit":null,"operatingIncome":-56027000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":32.62,"previousClose":32.51,"fiftyTwoWeekHigh":35.79,"fiftyTwoWeekLow":18.55,"fiftyTwoWeekRange":"18.55 - 35.79","fiftyDayAverage":31.97,"twoHundredDayAverage":26.97,"beta":0.98,"enterpriseValue":2102227200,"forwardPE":-7.2,"priceToBook":4.76,"priceToSales":2960.01,"enterpriseToRevenue":2430.32,"enterpriseToEbitda":-6.88,"pegRatio":0,"ebitda":-305696000,"ebitdaMargin":0,"freeCashflow":-126271376,"operatingCashflow":-222160992,"totalDebt":1908000,"debtToEquity":0.4,"currentRatio":8.92,"returnOnAssets":-30.9,"returnOnEquity":-48.9,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":57.29,"targetHighPrice":90,"targetLowPrice":38,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.3,"institutionHeldPercent":96.4,"sharesOutstanding":78492072,"floatShares":72361056,"sharesShort":7599353,"shortRatio":6.65,"shortPercentOfFloat":9.7,"epsTrailing":-4.27,"epsForward":-4.56,"revenuePerShare":0.01,"bookValue":6.85,"officers":[{"age":63,"name":"Mr. Anthony S. Marucci M.B.A.","title":"Founder, President, CEO & Director"},{"age":66,"name":"Dr. Tibor  Keler Ph.D.","title":"Founder, Chief Scientific Officer & Executive VP"},{"age":54,"name":"Mr. Sam  Martin CPA","title":"Senior VP, CFO, Secretary & Treasurer"},{"age":53,"name":"Ms. Elizabeth  Crowley","title":"Chief Product Development Officer & Senior VP"},{"age":68,"name":"Dr. Margo  Heath-Chiozzi M.D.","title":"Senior Vice President of Regulatory Affairs"},{"age":80,"name":"Prof. Joseph P. Schlessinger Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":50,"name":"Ms. Sarah  Cavanaugh","title":"Senior Vice President of Corporate Affairs & Administration"},{"age":56,"name":"Mr. Freddy A. Jimenez Esq.","title":"Senior VP & General Counsel"}],"industry":"Biotechnology","irWebsite":"http://www.avantimmune.com/","website":"https://www.celldex.com","phone":"908 200 7500"}}